Michael Kremer, Heidi Williams and I have an article in a Berkeley economics journal, Advance Market Commitments: A Policy to Stimulate Investment in Vaccines for Neglected Diseases which looks at the economic arguments for Advance Market Commitments.
CGD Policy Blogs
CNN reports on the development of a vaccine for Ebola.
On Friday, Merck received FDA approval for its new oral rotavirus vaccine, RotaTeq, and will begin domestic distribution within a week. At a cost of $187.50 for the three-dose series, RotaTeq is one of the most expensive vaccines to date; by 2009, the company forecasts that the vaccine could bring in as much as $500 million in annual revenue.
According to the New York Times: